- Fee assured
- Awaiting verification
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Face-to-face consultations
- Phone consultations
- Video consultations
Last updated: 14 Apr 2020
- Home chemotherapy
Dr Shah trained at Guy’s and St Thomas’ Hospitals between 1988 and 1994, obtaining a First Class Honours Intercalated BSc in Experimental Pathology.
He undertook medical training at The London Chest Hospital, Hammersmith Hospital, University College London, Guy’s Hospital and The Royal Marsden. He obtained Membership of the Royal College of Physicians of London in 1997.
Dr Shah was awarded a Clinical Research Fellowship by The Imperial Cancer Research Fund undertaking a period of research looking at abnormal genes in pancreatic cancer and utilising this to try and develop a cancer specific viral gene therapy. This work led to the award of a PhD.
Dr Shah subsequently trained to become a specialist in Medical Oncology at The Royal Marsden Hospital and was awarded an ASCO Foundation Merit Award in 2005. He was appointed Consultant Medical Oncologist at the Kent Oncology Centre in 2006.
Dr Shah provides specialist services in cancer systemic therapy to 3 acute NHS Trusts. He also provides services as a private medical oncologist at several hospitals.
He is involved in training future medical oncologists and has an extensive role in clinical research. He has served on the NCRI Lung Group, acted as chairman of the Kent Lung Network Lead and continues to be the lead for research at his cancer centre.
Dr Shah is heavily involved in clinical research. He acts as principal investigator on many trials in his centre and has been a major champion in the introduction of immunotherapy into routine clinical practice within Kent.
He has published widely and regularly speaks both nationally and internationally on cancer issues.
Areas of interest
Specialist in cancers of the chest and colorectal tract (e.g. lung cancer, mesothelioma, colorectal cancer,); Specialist in unknown primary malignancies; Specialist in acute oncology; Specialist in phase II and III clinical trials; Specialist in immunotherapy
- Mrs Christine Smith
- Kent Oncology Centre The Maidstone Hospital Hermitage Lane Maidstone ME16 9QQ
- 01622 227035
Current NHS consultant posts held
Consultant Medical Oncologist since 2006 at Kent Oncology Centre, Maidstone. NHS roles at Maidstone and Tunbridge Wells NHS Trust and Darent Valley Hospital
Phase II/III clinical trials of novel therapeutic agents. I have been involved in cancer clinical trials using a range of investigational medicinal products such as BIBW2992, BIBF1120, MAGE A3, NGR-hTNF, Temilumomab, Defactinib, Olaparib Some of these are now licensed drugs.
ASCO Foundation Merit Award 2005
Gregorc V et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19(6):799-811.
Talbot T et al. The burden of neutropenic sepsis in patients with advanced lung cancer treated with single agent docetaxel: a retrospective study. In press
Rosell, Dafni, Felip, et al. Erlotinib and Bevacizumab in patients with advanced non small cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single arm, phase 2 trial. Lancet Resp Med 2017;
Yang JC, Sequist LV et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016 Nov;27(11):2103-2110.
Lal R et al. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2015 Aug;89(2):154-60
Sequist LV t al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34
O’Hanlon-Brown, Waters J, Shah R. Non small cell lung cancer: Immunotherapy a new treatment modality. ICMJE 2015.
Nicolson MC et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol. 2013 Jul;8(7):930-9
Spyridon Gennatas et al. Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. BMC Cancer 2013, 13:207
Papa S et al. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. J Thorac Oncol. 2013 Apr 8.
Minchom A, Chan S, Melia W, Shah R. An unusual case of pancreatic cancer with leptomeningeal infiltration. J Gastrointest Cancer. 2010 Jun;41(2):107-9
Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones RL, Blake P, Gabra H, Hall G, Gore ME, Kaye SB. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol ( 2009); 20(11):1787-93.
- BSc Hons and MBBS University of London 1994
- MRCP (UK) Royal College of Physicians of London 1997
- PhD Imperial College London 2002
- FRCP Royal College of Physicians of London 2010
Reference number 4109673
Details of entry to specialist register
- CCT in Medical Oncology, 2005
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.